MENLO PARK, Calif., May 22 /PRNewswire-FirstCall/ -- XTENT, Inc. , developer of customizable drug-eluting stent (DES) systems, will host an analyst webcast, slide presentation and telebriefing to review the CUSTOM II six-month data Tuesday, May 22 at 2:00p.m. EDT (8:00p.m. CEST).
The event will follow the presentation of CUSTOM II six-month data by Professor Eberhard Grube, MD, chief of cardiology at the Helios Heart Center in Siegburg, Germany and principal investigator of the CUSTOM II trial, during the late-breaking clinical trials section of the annual EuroPCR meeting on Tuesday, May 22. Dr. Grube’s presentation is slated for 6:11 to 6:17 pm (CEST)/12:11 to 12:17 pm (EDT) in Room I, Main Arena, Barcelona International Convention Center.
The webcast, teleconference and slide presentation can be accessed via the investor relations section of the Company’s website at http://investor.xtentinc.com/events.cfm or by calling 800-361-0912 (from the U.S.), 913-981-5559 (international). Please dial in or access the website 5 to 10 minutes prior to the beginning of the call. If you do dial-in, please also view the slides via the webcast. The webcast will be archived on the website for a minimum of three months, and can be accessed at the investor relations portion of the company’s website at http://investor.xtentinc.com
About XTENT
XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device. Note: XTENT(R) Custom NX(R) DES Systems have not been approved for sale by any regulatory authority.
Information about XTENT is available at our website at http://www.xtentinc.com.
XTENT, Inc.
CONTACT: Investor Relations: Tim Kahlenberg, Chief Financial Officer ofXTENT, Inc., +1-650-475-9400, tkahlenberg@xtentinc.com; or Media Relations:Danielle Bertrand, +1-415-946-1056, dbertrand@weisscommpartners.com, forXTENT, Inc.
Web site: http://www.xtentinc.com/
